Siemens Healthineers and Novo join forces to advance care for people living with MASLD and MASH
by Siemens Healthineers · News-MedicalSiemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). The companies are engaged in several projects to strengthen disease awareness, support earlier assessment of the disease, and help expand patient access to non-invasive blood testing.
Supporting earlier assessment and wider access through non-invasive testing
Assessment of liver fibrosis has relied heavily on specialized imaging equipment or invasive procedures such as liver biopsy, which are not widely accessible to patients. Clinicians recognize that liver biopsy remains necessary for certain patients, though there is growing consensus about the critical role that non-invasive tests play in the management of MASLD/MASH.
As the global burden of metabolic disease rises, liver health experts are sounding the alarm about the importance of identifying the disease before it advances to fibrosis, cirrhosis, or other serious complications. The collaboration between Siemens Healthineers, a leading in vitro diagnostics company, and Novo, a global leader in cardiometabolic health, seeks to advance solutions that make MASH assessment more accessible and actionable across the healthcare continuum. This includes broader awareness and adoption of noninvasive testing (NIT) approaches that can provide clinicians with valuable information about liver health while helping reduce reliance on invasive procedures.
Michelle Long, senior international medical director for MASH, NovoEarlier triage is one of the most important opportunities to improve the future of MASH care. Our collaboration recognizes that patients, clinicians, laboratories, health systems, and industry partners all have a role to play in creating a more effective pathway for liver disease assessment and management."
Source: